Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis

Journal of Dermatological Treatment

Volumn 16, Issue 3, 2005, Pages 158-164

  Lowe, Nicholas ^a   Feldman, Steven R ^b   Sherer, Daniel ^c   Weiss, Jonathan ^d   Shavin, Joel S ^d   Lin, Yin Lui ^e   Foley, Valerie ^e   Soto, Pascale ^f  

^a Clinical Research Specialists   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Gwinnett Clinical Research Center   (United States)

^e Galderma R and D Inc   (United States)

^f Galderma R and D   (France)

Author keywords

Clobetasol propionate; Plaque type psoriasis; Quality of life; Remission; Skin atrophy; Telangiectasia

Indexed keywords

CLOBETASOL PROPIONATE; CLOBEX LOTION; TEMOVATE E;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; IRRITANT DERMATITIS; LOTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; TELANGIECTASIA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANALYSIS OF VARIANCE; CLOBETASOL; DERMATOLOGIC AGENTS; EMOLLIENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 25444469167     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630510041060     Document Type: Article

References (12)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-96.
2. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark AR. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-37.
3. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269-74.
4. Rapp SR, Feldman SR, Fleischer AB Jr, Reboussin DM, Exum ML. Health related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sheretz EF, Anderson R, editors. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker, 1998:125-45.
5. Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144(Suppl 58):33-6.
6. Al Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42:796-802.
7. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-32.
8. Amin S, Cornell R, Soughton R, Maibach H. In: Psoriasis, 3rd edn. New York: Marcel Dekker, 1998:453-67.
9. Katz HI, Ngo TH, Prawer SE, Mastbaum LI, Mooney JJ, Samson CR. Superpotents steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol. 1987;16:804-11.
10. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of severe psoriasis. Am J Clin Dermatol. 2003;4:221-4.
11. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72:407-11.
12. Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004;74:201-6.